PTGER4 and myeloid sarcoma: Receptor levels of EP4 were significantly lower in MS lesions (p = 0.0018) compared to NNCs, whereas EP2 levels were increased in MS lesions compared to NNCs (p < 0.0001) (Fig. 4b, c).